Biopharmaceutical major AstraZeneca plc (NASDAQ: AZN) recently revealed that it has signed a Master Collaboration Agreement with a molecular diagnostics company, Amoy Diagnostics Co. Ltd. Following the news, shares of the company declined marginally to close at $68.61 on Monday. The agreement entails the development and commercialization of AmoyDx assays that may cover any type of indication or biomarker for companion diagnostic (CDx) use with AstraZeneca medicines globally.
https://www.tipranks.com/news/astrazeneca-amoy-diagnostics-to-develop-diagnostics-programs?utm_source=advfn.com&utm_medium=referral